Small but mighty: T-replete cords for myeloid disease.
作者信息
LaBelle James L
机构信息
Department of Pediatrics, Section of Hematology and Oncology, University of Chicago, Chicago, IL.
出版信息
Blood Adv. 2023 May 23;7(10):2153-2154. doi: 10.1182/bloodadvances.2023009746.
Abstract
摘要
相似文献
1
Small but mighty: T-replete cords for myeloid disease.
Blood Adv. 2023 May 23;7(10):2153-2154. doi: 10.1182/bloodadvances.2023009746.
2
Differences in Aspergillus-specific immune recovery between T-cell-replete and T-cell-depleted hematopoietic transplants.
Eur J Haematol. 2015 Dec;95(6):551-7. doi: 10.1111/ejh.12531. Epub 2015 Mar 16.
3
Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study).
Leukemia. 2023 Nov;37(11):2330-2333. doi: 10.1038/s41375-023-02033-5. Epub 2023 Sep 15.
4
Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children.
Sci China Life Sci. 2019 Jan;62(1):104-111. doi: 10.1007/s11427-017-9302-1. Epub 2018 May 30.
5
T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?
Expert Rev Hematol. 2019 Sep;12(9):733-752. doi: 10.1080/17474086.2019.1642103. Epub 2019 Jul 19.
6
Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
Clin Transplant. 2018 Apr;32(4):e13220. doi: 10.1111/ctr.13220. Epub 2018 Feb 28.
7
Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease.
Curr Opin Hematol. 2005 Jan;12(1):45-54. doi: 10.1097/01.moh.0000148762.05110.56.
8
T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
Bone Marrow Transplant. 2014 Aug;49(8):999-1008. doi: 10.1038/bmt.2014.62. Epub 2014 May 19.
9
Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
Br J Haematol. 2021 Jun;193(5):1004-1008. doi: 10.1111/bjh.17423. Epub 2021 Apr 6.
10
Ex vivo-expanded hematopoietic cell graft recipients exhibit T cell repertoire diversity similar to that seen after conventional stem cell transplants.
J Hematother Stem Cell Res. 2001 Feb;10(1):53-66. doi: 10.1089/152581601750098237.
本文引用的文献
1
T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy.
Blood Adv. 2023 May 23;7(10):2155-2165. doi: 10.1182/bloodadvances.2022009253.
2
Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications.
Front Cell Dev Biol. 2022 Apr 6;10:836594. doi: 10.3389/fcell.2022.836594. eCollection 2022.
3
Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia.
Leukemia. 2022 Apr;36(4):1132-1138. doi: 10.1038/s41375-021-01474-0. Epub 2021 Nov 24.
4
Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Transplant Cell Ther. 2021 Apr;27(4):334.e1-334.e11. doi: 10.1016/j.jtct.2021.01.023. Epub 2021 Jan 28.
5
Cord blood transplantation recapitulates fetal ontogeny with a distinct molecular signature that supports CD4 T-cell reconstitution.
Blood Adv. 2017 Nov 2;1(24):2206-2216. doi: 10.1182/bloodadvances.2017010827. eCollection 2017 Nov 14.
6
Cord-Blood Transplantation in Patients with Minimal Residual Disease.
N Engl J Med. 2016 Sep 8;375(10):944-53. doi: 10.1056/NEJMoa1602074.
7
Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells.
Blood. 2015 Dec 24;126(26):2882-91. doi: 10.1182/blood-2015-06-654780. Epub 2015 Oct 8.
8
Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome.
Blood. 2014 Jan 2;123(1):126-32. doi: 10.1182/blood-2013-05-502385. Epub 2013 Nov 1.
9
Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.
Biol Blood Marrow Transplant. 2011 Oct;17(10):1460-71. doi: 10.1016/j.bbmt.2011.02.001. Epub 2011 Mar 1.
10
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.
Blood. 2009 Nov 5;114(19):4293-9. doi: 10.1182/blood-2009-05-220525. Epub 2009 Aug 25.
Zotero 插件